Table 4.
Seizure outcomes by drug
| Events/total | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | |
|---|---|---|---|---|---|---|---|
| Time to 12-month remission—intention to treat | |||||||
| Number at risk | |||||||
| Carbamazepine | 254/362 | 347 | 120 | 73 | 41 | 16 | 6 |
| Gabapentin | 215/359 | 337 | 141 | 76 | 45 | 25 | 7 |
| Lamotrigine | 245/365 | 356 | 126 | 59 | 36 | 19 | 4 |
| Topiramate | 225/358 | 338 | 126 | 74 | 50 | 24 | 5 |
| Oxcarbazepine | 128/200 | 189 | 58 | 21 | 3 | ||
| Percentage of 12-month remission (95% CI) | |||||||
| Carbamazepine | 254/362 | 36 (31 to 41) | 60 (55 to 66) | 69 (63 to 74) | 77 (72 to 82) | 82 (77 to 87) | 85 (79 to 91) |
| Difference in percentage of 12-month remission compared with carbamazepine (95% CI) | |||||||
| Gabapentin | 215/359 | −12 (−19 to −5) | −9 (−16 to −1) | −6 (−13 to 2) | −6 (−14 to 1) | −9 (−17 to −1) | −9 (−18 to 0) |
| Lamotrigine | 245/365 | −7 (−13 to 0) | −3 (−11 to 4) | 3 (−4 to 11) | −1 (−8 to 7) | −3 (−10 to 5) | −2 (−11 to 7) |
| Topiramate | 225/358 | −3 (−10 to 4) | −5 (−13 to 2) | −2 (−10 to 5) | −6 (−14 to 1) | −7 (−14 to 1) | −4 (−14 to 6) |
| Oxcarbazepine | 128/200 | −1 (−11 to 9) | −3 (−13 to 7) | −1 (−12 to 9) | −2 (−15 to 10) | ||
| Time to 12-month remission—per protocol | |||||||
| Number at risk | |||||||
| Carbamazepine | 164/352 | 222 | 47 | 26 | 13 | 5 | |
| Gabapentin | 126/351 | 194 | 42 | 16 | 8 | 5 | |
| Lamotrigine | 170/358 | 264 | 66 | 25 | 16 | 6 | |
| Topiramate | 138/353 | 203 | 40 | 15 | 5 | 3 | |
| Oxcarbazepine | 80/195 | 117 | 25 | 6 | |||
| Percentage of 12-month remission (95% CI) | |||||||
| Carbamazepine | 164/352 | 29 (24 to 34) | 44 (39 to 50) | 48 (42 to 53) | 50 (44 to 55) | 53 (47 to 58) | |
| Difference in percentage of 12-month remission compared with carbamazepine (95% CI) | |||||||
| Gabapentin | 126/351 | −9 (−16 to −3) | −9 (−17 to −2) | −9 (−17 to −1) | −9 (−17 to −1) | −12 (−20 to −4) | |
| Lamotrigine | 170/358 | −4 (−11 to 3) | 0 (−8 to 7) | 4 (−4 to 12) | 5 (−3 to 12) | 3 (−5 to 11) | |
| Topiramate | 138/353 | −4 (−11 to 3) | −6(−13 to 2) | −6 (−14 to 1) | −6 (−14 to 2) | −8 (−16 to 0) | |
| Oxcarbazepine | 80/195 | −2 (−12 to 7) | −7(−17 to 4) | −5 (−16 to 6) | |||
| Time to 24 months remission—intention to treat | |||||||
| Number at risk | |||||||
| Carbamazepine | 168/362 | 295 | 116 | 71 | 28 | 8 | |
| Gabapentin | 132/359 | 283 | 125 | 74 | 36 | 8 | |
| Lamotrigine | 155/365 | 296 | 120 | 67 | 30 | 9 | |
| Topiramate | 140/358 | 284 | 124 | 80 | 41 | 12 | |
| Oxcarbazepine | 68/200 | 138 | 39 | 5 | |||
| Percentage of 24 month remission (95% CI) | |||||||
| Carbamazepine | 168/362 | 32 (27 to 37) | 50 (44 to 56) | 57 (51 to 63) | 65 (58 to 72) | 69 (61 to 78) | |
| Difference in percentage of 24 month remission compared with carbamazepine (95% CI) | |||||||
| Gabapentin | 132/359 | −13 (−20 to −6) | −12 (−21 to −4) | −7 (−16 to 2) | −7 (−17 to 4) | −8 (−20 to 4) | |
| Lamotrigine | 155/365 | −6 (−13 to 1) | −7 (−15 to 1) | −1 (−9 to 8) | −3 (−13 to 6) | −5 (−17 to 6) | |
| Topiramate | 140/358 | −5 (−12 to 3) | −7 (−16 to 1) | −6 (−15 to 3) | −11 (−21 to −2) | −8 (−20 to 4) | |
| Oxcarbazepine | 68/200 | −4 (−15 to 7) | −6 (−19 to 6) | 0 (−18 to 17) | |||
| Time to first seizure—intention to treat | |||||||
| Number at risk | |||||||
| Carbamazepine | 259/362 | 126 | 92 | 53 | 34 | 17 | 4 |
| Gabapentin | 288/359 | 83 | 53 | 39 | 18 | 7 | 1 |
| Lamotrigine | 290/365 | 106 | 76 | 48 | 29 | 10 | 5 |
| Topiramate | 268/358 | 112 | 76 | 50 | 33 | 13 | 4 |
| Oxcarbazepine* | 144/200 | 67 | 42 | 11 | |||
| Percentage of first seizure (95% CI) | |||||||
| Carbamazepine | 259/362 | 63 (58 to 68) | 69 (64 to 73) | 73 (68 to 78) | 73 (68 to 78) | 74 (69 to 79) | 78 (69 to 87) |
| Difference in percentage of first seizure compared with carbamazepine (95% CI) | |||||||
| Gabapentin | 288/359 | 12 (5 to 19) | 11 (4 to 17) | 8 (1 to 14) | 9 (3 to 16) | 11 (3 to 18) | 6 (−4 to 17) |
| Lamotrigine | 290/365 | 7 (1 to 14) | 6 (0 to 13) | 7 (0 to 13) | 8 (2 to 15) | 10 (3 to 17) | 5 (−5 to 15) |
| Topiramate | 268/358 | 4 (−3 to 11) | 5 (−2 to 11) | 3 (−4 to 9) | 5 (−2 to 12) | 4 (−3 to 11) | 0 (−10 to 10) |
| Oxcarbazepine* | 144/200 | 1 (−8 to 10) | 1 (−8 to 10) | 5 (−4 to 15) | |||
*
Figures in this row for use data for oxcarbazepine and carbamazepine only from patients randomised after June 1, 2001.